From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Vernmark, Karolina ^a   Albertsson, Maria ^a   Björnsson, Bergthor ^a   Gasslander, Thomas ^a   Sandström, Per ^a   Sun, Xiao Feng ^a   Holmqvist, Annika ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Bevacizumab; Metronomic capecitabine; Mucinous adenocarcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLON BIOPSY; COLON POLYP; COLON TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENERAL CONDITION DETERIORATION; HEMICOLECTOMY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG EMBOLISM; MUCINOUS ADENOCARCINOMA; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; POSTOPERATIVE INFECTION; RECTUM HEMORRHAGE; STOMACH PAIN; TUMOR REGRESSION; WEIGHT REDUCTION; ADENOCARCINOMA, MUCINOUS; PALLIATIVE THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE;

EID: 84946560035     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1908-3     Document Type: Article

References (23)

1. Zhang H, Evertsson S, Sun X. Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol. 1999;14(6):1057-61.
2. Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012;65(5):381-8.
3. Hyngstrom JR , Hu CY, Xing Y, You YN, Feig BW, Skibber JM et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19(9):2814-21.
4. Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg. 1985;72(9):715-8.
5. Nozoe T , Anai H, Nasu S, Sugimachi K. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol. 2000;75(2):103-7.
6. Akino F , Mitomi H, Nakamura T, Ohtani Y, Ichinoe M, Okayasu I. High apoptotic activity and low epithelial cell proliferation with underexpression of p21(WAF1/CIP1) and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type. Am J Clin Pathol. 2002;117(6):908-15.
7. Connelly JH, Robey-Cafferty SS, Cleary KR. Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. Arch Pathol Lab Med. 1991;115(10):1022-5.
8. Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol. 1988;41(10):1068-72.
9. Messerini L , Vitelli F, De Vitis LR, Mori S, Calzolari A, Palmirotta R et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. J Pathol. 1997;182(4):380-4.
10. Lupinacci RM, Mello ES, Coelho FF, Kruger JA, Perini MV, Pinheiro RS et al. Prognostic implication of mucinous histology in resected colorectal cancer liver metastases. Surgery. 2014;155(6):1062-8.
11. Shin US, Yu CS, Kim JH, Kim TW, Lim SB, Yoon SN et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol. 2011;18(8):2232-9.
12. Younes M, Katikaneni PR, Lechago J. The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer. 1993;72(12):3588-92.
13. Niv Y. Mucin and colorectal cancer metastasis. Am J Gastroenterol. 1994;89(5):665-9.
14. Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186-92.
15. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387-95.
16. Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer. 2012;48(1):24-9.
17. Miger J, Holmqvist A, Sun XF, Albertsson M. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol. 2014;31(3):870.
18. Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol. 2015;32(3):54.
19. Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med. 2014;4(4):58-67.
20. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013;109(7):1725-34.
21. Baranyai Z, Jósa V, Krzystanek M, Eklund AC, Szász AM, Szállási Z. Evaluation of thrombocytosis as predictive factor in colorectal cancer. Magy Seb. 2013;66(6):331-7.
22. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108(8):1757-64.
23. Carstens H, Albertsson M. Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma. Acta Oncol. 2007;46(6):866-8.